论文部分内容阅读
目的探讨血浆D-二聚体检验对急性白血病患者病情进展及疗效评估的临床意义。方法选择180例急性白血病患者作为观察组研究对象,另外选择同期60例健康体检者作为对照组研究对象,应用免疫比浊法检测血浆D-二聚体水平。对初治期(180例)、缓解期(123例)、复发期(38例)患者进行动态监测D-二聚体,并对比分析急性非淋巴细胞白血病(ANLL)与其他类型白血病患者的血浆D-二聚体水平。结果与对照组相比,初治期、复发期急性白血病患者的D-二聚体水平均明显升高(均P<0.05);与缓解期相比,初治期、复发期急性白血病患者D-二聚体水平均明显升高(均P<0.05);对照组缓解期急性白血病患者D-二聚体水平差异无统计学意义(P>0.05);初治期与复发期急性白血病患者D-二聚体水平差异无统计学意义(P>0.05)。与其他类型急性白血病相比,ANLL患者初治期D-二聚体水平明显升高(P<0.05),但缓解期两组D-二聚体水平比较,差异没有统计学意义(P>0.05)。结论血浆D-二聚体可反映急性白血病患者病情变化,动态监测D-二聚体水平有利于病情观察及疗效评估。
Objective To investigate the clinical significance of plasma D-dimer test in patients with acute leukemia and its progression. Methods A total of 180 patients with acute leukemia were selected as observation group. Sixty healthy subjects at the same period were selected as the control group. Plasma D-dimer levels were measured by immunoturbidimetry. D-dimer was dynamically monitored in patients with early stage (180 cases), remission stage (123 cases) and recurrent stage (38 cases), and plasma levels of plasma in patients with acute non-lymphocytic leukemia (ANLL) and other types of leukemia D-dimer level. Results Compared with the control group, the levels of D-dimer in the newly diagnosed and relapsed acute leukemia patients were significantly increased (all P <0.05). Compared with the remission stage, - dimer levels were significantly increased (all P <0.05); control group acute leukemia patients with no significant difference in D-dimer levels (P> 0.05); early and recurrent acute leukemia patients D - dimer level difference was not statistically significant (P> 0.05). Compared with other types of acute leukemia, the level of D-dimer in the initial stage of ANLL patients was significantly increased (P <0.05), but there was no significant difference in the level of D-dimer between the two groups (P> 0.05 ). Conclusion Plasma D-dimer can reflect the changes of patients with acute leukemia, dynamic monitoring of D-dimer level is conducive to the observation of the disease and efficacy evaluation.